Corpay Inc (NYSE: CPAY): Stock That Needs Special Handling

Currently, there are 69.68M common shares owned by the public and among those 67.29M shares have been available to trade.

The company’s stock has a 5-day price change of 6.43% and 7.50% over the past three months. CPAY shares are trading 9.57% year to date (YTD), with the 12-month market performance up to 33.41% higher. It has a 12-month low price of $247.10 and touched a high of $385.30 over the same period. CPAY has an average intraday trading volume of 490.94K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.47%, 3.19%, and 18.85% respectively.

Institutional ownership of Corpay Inc (NYSE: CPAY) shares accounts for 93.68% of the company’s 69.68M shares outstanding.

It has a market capitalization of $25.85B and a beta (3y monthly) value of 1.27. The stock’s trailing 12-month PE ratio is 26.44, while the earnings-per-share (ttm) stands at $14.02. The company has a PEG of 1.82 and a Quick Ratio of 1.05 with the debt-to-equity ratio at 2.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.16% over the week and 2.07% over the month.

Earnings per share for the fiscal year are expected to increase by 12.20%, and 15.96% over the next financial year. EPS should grow at an annualized rate of 14.55% over the next five years, compared to 8.43% over the past 5-year period.

Looking at the support for the CPAY, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on January 14, 2025, with the firm’s price target at $430. Wolfe Research coverage for the Corpay Inc (CPAY) stock in a research note released on January 08, 2025 offered a Outperform rating with a price target of $420. Wolfe Research was of a view on September 03, 2024 that the stock is Peer Perform, while Wells Fargo gave the stock Equal Weight rating on June 05, 2024, issuing a price target of $285. Wolfe Research on their part issued Underperform rating on May 17, 2024.

Most Popular

Related Posts